Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ACS Announces New Editor-in-Chief of Chemical Research in Toxicology

Published: Friday, July 20, 2012
Last Updated: Friday, July 20, 2012
Bookmark and Share
Stephen S. Hecht will take over as Editor-in-Chief of Chemical Research in Toxicology in January 2013.

The American Chemical Society (ACS) has announced that Stephen S. Hecht, Ph.D., will take over as Editor-in-Chief of Chemical Research in Toxicology in January 2013.

Hecht is the Winston R. and Maxine H. Wallin Land Grant Professor of Cancer Prevention and American Cancer Society Professor at the Masonic Cancer Center at the University of Minnesota, Minneapolis, and currently serves as an Associate Editor of the Journal of Medicinal Chemistry.

Hecht will succeed Lawrence J. Marnett, Ph.D., who will retire from the journal at the end of this year.

Marnett, Mary Geddes Stahlman Professor of Cancer Research and professor of biochemistry, chemistry and pharmacology at Vanderbilt University, has served as Editor-in-Chief of Chemical Research in Toxicology since he helped found the journal in 1988.

Marnett will assist with the transition and remain with the journal in his current role through the end of 2012.

“Professor Hecht’s distinguished career, his experience in both chemical toxicology and medicinal chemistry and his vision for the future of the journal will serve him well as the editor of Chemical Research in Toxicology,” said Susan King, senior vice president of the Journals Publishing Group at ACS.

Hecht, elected an ACS Fellow in 2009, received his B.S. in chemistry from Duke University in 1964 and a Ph.D. in organic chemistry from the Massachusetts Institute of Technology in 1968.

He joined the Masonic Cancer Center in 1996, where his research interests center on elucidating the mechanisms of chemical carcinogenesis in humans, including those related to tobacco-induced cancer.

His group looks for carcinogen biomarkers and applies them to molecular epidemiology and cancer prevention, and more specifically, to the prevention of lung and esophageal cancer.

Outgoing Editor Marnett said of Hecht, “He is the second-leading author over the past 25 years of all the authors who have published in the journal. His work is very high quality, very rigorous and very chemical. He appreciates what the journal has meant in the community, and I know he’s very interested in seeing it flourish.”

Hecht has received numerous awards, including the Joseph Cullen Award from the American Society of Preventive Oncology in 2012, the Founders’ Award from the ACS Division of Chemical Toxicology in 2009 and the American Association for Cancer Research-Cancer Research and Prevention Foundation Award for Excellence in Cancer Prevention Research in 2006.

Chemical Research in Toxicology publishes new and original research on the chemical basis of toxic responses in living organisms.

That research includes how cells and organisms respond to chemical or biological toxic agents and how those agents can lead to disease.

Chemical Research in Toxicology received 10,444 total citations in 2011. The journal also has a high Impact Factor of 3.779, as reported by the 2011 Journal Citation Reports® (Thomson Reuters, 2012).


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Combining Chemotherapy With Immune-Blocking Drug Could Stop Cancer Growing Back
Giving patients a drug that blocks part of the immune system from going into overdrive might help prevent cancer coming back in some people.
Researchers Pioneer Use of Capsules to Save Materials
Wax capsule delivery systems can simplify a wide range of chemistry transformations.
Photoredox Catalyst Unlocks New Pathways for Nickel Chemistry
Using a light-activated catalyst, researchers have unlocked a new pathway in nickel chemistry to construct carbon-oxygen (C-O) bonds that would be highly valuable to pharmaceutical and agrochemical industries.
Scientists Determine How Antibiotic Gains Cancer-Killing Sulfur Atoms
In a discovery with implications for future drug design scientists have shown an unprecedented mechanism for how a natural antibiotic with antitumor properties incorporates sulfur into its molecular structure, an essential ingredient of its antitumor activity.
Familiar Drugs May Block Ebola Virus Infection
A well-known class of molecules, many of which are already in use therapeutically, may be able to block the Ebola virus’s entry into cells and halt the disease in its tracks, according to researchers at the University of Illinois at Chicago.
New Extra ‘Sticky’ Microgel Could Revolutionise Bladder Cancer Treatment
Researchers have designed a new super-efficient way of delivering an anti-cancer drug which could extend and improve the quality of life for bladder cancer patients - and perhaps save lives.
Common Class of ‘Channel Blocking’ Drugs May Find a Role in Cancer Therapy
Discoveries in fruit flies prompt unusual treatment of patient with metastatic disease.
Common Medications Could Delay Brain Injury Recovery
Drugs used to treat common complaints could delay the recovery of brain injury patients according to research by University of East Anglia (UEA) and University of Aberdeen scientists, published today in Brain Injury.
Scientists Make Strides in Therapy Preventing Addiction Relapse
Single Injection of Drug Candidate Prevents Meth Relapse in Animal Models.
New Clot-Busting Treatments Target Number One Killer
Australian researchers funded by the National Heart Foundation are a step closer to a safer and more effective way to treat heart attack and stroke via nanotechnology.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!